Do you find it interesting the company remains under a partial clinical hold which by Linda's admission has delayed the trial considerably?? Do you find in interesting that another bio that underwent a partial clinical hold after nwbo has already had their hold lifted? Are you familier with the FR rule that pertains to small cap bio's and how there is a strong correlation with a low market cap and failure (for whatever reasons I personally believe good news has a way of leaking). Are you aware of nwbo's current market cap? Do you agree that it is certainly possible that the interim efficacy results weren't as great as expected and that it happens all the time in clinical trials? Do you understand that most clinical trials fail? Please explain to me what part seems so outrageous..
News 
Market Data 
Discover 
